CBT gets rights to CTLA-4 antibody

Crown Bioscience International Inc. (TPEx:6554) granted CBT Pharmaceuticals Inc. (Pleasanton, Calif.) exclusive, worldwide rights to CBT-509, a human mAb against cytotoxic T-lymphocyte associated protein 4 (CTLA-4; CTLA4; CD152). Crown is eligible for up to $47 million in milestones plus royalties.

CBT said it will evaluate the compound as a monotherapy in the Phase I portion of a Phase I/II trial and then in combination with other therapies in its immuno-oncology pipeline...